On April 24, 2020 FUJIFILM Toyama Chemical Co., Ltd. (President: Junji Okada) reported that it has begun a phase I clinical trial of anticancer agent "FF-21101" in Japan, for the treatment of cancer patients with refractory advanced solid tumors, who have experienced a recurrence or remote metastasis (Press release, Fujifilm, APR 24, 2020, View Source [SID1234556574]). The study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of FF-21101 for advanced ovarian, biliary tract, and head-and-neck solid tumor cancers.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
FUJIFILM Corporation developed FF-21101, which employs an antibody that conjugates radioisotope (RI) of yttrium (90Y)*1 (armed antibody*2). Through antigen-antibody reactions*3, FF-21101 accumulates selectively in cancer tissues that express the antigen P-cadherin*4, and specifically delivers radiation emitted by yttrium (90Y) to the cancer tissues. By targeting P-cadherin, the investigational therapy is expected to demonstrate efficacy in shrinking solid tumors.
In 2016, FUJIFILM Corporation began a U.S. clinical study of FF-21101 for the treatment of advanced solid tumors in cancer patients.
In addition to FF-21101, FUJIFILM Toyama Chemical is actively working to develop therapeutic radiopharmaceuticals such as F-1515 (lutetium [177Lu] DOTA-octreotate) for neuroendocrine tumors*5, and F-1614 (3-iodobenzylguanidine [131I]) for refractory pheochromocytoma*6, among others.
FUJIFILM Toyama Chemical is contributing to healthcare by striving to improve medicine and enhance the quality of life.
* 1 A radioisotope that emits radiation suited for treatment (beta rays). Its physical half-life is 64 hours.
* 2 An antibody that has been chemically linked with RI and toxins, it is expected to attack cancer tissues.
* 3 A phenomenon whereby antigens, such as foreign substances that have entered the body, or specific proteins that express in cancer, combine with the protein antibodies created by immune cells.
* 4 A protein that is known to express on the cell surface of numerous solid cancers and be involved in cancer’s proliferation and metastasis.
* 5 A tumor derived from neuroendocrine cells that distribute widely throughout the body. Although it develops in a variety of organs all over the body, it occurs especially frequently in the pancreas, digestive tract, and the lungs.
* 6 A neuroendocrine tumor that develops mainly from the adrenal medulla (a part of the adrenal gland located above the kidney, consisting of cells that secrete hormones).